ZK7 Stock Overview
A clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Conduit Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.17 |
| 52 Week High | US$0.28 |
| 52 Week Low | US$0.15 |
| Beta | 2.17 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -29.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZK7 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -10.8% | -0.5% | -0.07% |
| 1Y | n/a | -10.4% | -0.5% |
Return vs Industry: Insufficient data to determine how ZK7 performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how ZK7 performed against the German Market.
Price Volatility
| ZK7 volatility | |
|---|---|
| ZK7 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: ZK7's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ZK7's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 7 | Dave Tapolczay | www.conduitpharma.com |
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave’s disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California.
Conduit Pharmaceuticals Inc. Fundamentals Summary
| ZK7 fundamental statistics | |
|---|---|
| Market cap | €12.85m |
| Earnings (TTM) | -€2.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.8x
P/E RatioIs ZK7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZK7 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.42m |
| Earnings | -US$2.41m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.033 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -31.7% |
How did ZK7 perform over the long term?
See historical performance and comparison